>

Manvinder Banga - GlaxoSmithKline PLC Non-Executive Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:6em;padding-top: 0px;;'>G</div>
GSK -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Mr. Manvinder Singh Banga is Senior NonExecutive Independent Director of the Company since May 5, 2016. Prior to joining GSK, Vindi spent 33 years at Unilever plc, where his last role was President of the Global Foods, Home and Personal Care businesses, and he was a member of the Unilever Executive Board. Vindi sat on the Prime Minister of Indias Council of Trade Industry from 2004 to 2014, and was on the Board of Governors of the Indian Institute of Management, Ahmedabad. Vindi is also the recipient of the Padma Bhushan, one of Indias highest civilian honours. Between 2015 and 2016, Vindi was a NonExecutive Director of Thomson Reuters Corporationrationand a member of its HR committee. Vindi was also previously Chairman of the Supervisory Board of Mauser Group. Vindi is a Partner at private equity investment firm Clayton Dubilier Rice. He is also Chairman of Kalle GmbH, Senior Independent Director of Marks Spencer Group plc, a member of its Nomination Committee and Chairman of its Remuneration Committee. Vindi is a NonExecutive Director of the Confederation of British Industry, a Director of High Ridge Brands Co, a member of the Holdingham International Advisory Board and Chair of the Board of Trustees of Marie Curie. He is also on the Governing Board of the Indian School of Business, Hyderabad, and is a member of the Indo UK CEO Forum.
Age: 62  Director Since 2016      
(44) 20 8047 7807  www.gsk.com

Management Efficiency

The company has Return on Asset of 0.07 % which means that on every $100 spent on asset it made $0.07 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.9 % implying that it generated $0.9 on every 100 dollars invested.
The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Anne MulcahyJohnson Johnson
2012
Robert KidderMerck Company
2005
William PerezJohnson Johnson
2007
Michael EskewEli Lilly And Company
2008
Joseph EchevarriaPfizer
2015
Pierre LandoltNovartis AG
1996
Theodore SamuelsBristol Myers Squibb Company
2017
Vicki SatoBristol Myers Squibb Company
2017
Don CornwellPfizer
1997
Frans HoutenNovartis AG
2017
James KiltsPfizer
2007
Alan LacyBristol Myers Squibb Company
2008
Raul AlvarezEli Lilly And Company
2009
Jamere JacksonEli Lilly And Company
2016
Robert BertoliniBristol Myers Squibb Company
2017
Joseph BoccuziAllergan Plc
2017
Ann FudgeNovartis AG
2008
Catherine KlemaAllergan Plc
2016
Adriane BrownAllergan Plc
2017
Karen VousdenBristol Myers Squibb Company
2018
Tim JacksonSmithAstrazeneca PLC
2015

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 99,437 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive DirectorView
Lynn Elsenhans, Independent Non-Executive DirectorView
Luke Miels, President - Global PharmaceuticalsView
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive DirectorView
Daniel Podolsky, Non-Executive Independent DirectorView
Emma Walmsley, Chief Executive Officer, Executive DirectorView
Luc Debruyne, President - Global VaccinesView
Andrew Witty, CEO, Executive DirectorView
Brian McNamara, Chief Executive Officer - GSK Consumer HealthcareView
Roy Anderson, Non-Executive Independent DirectorView
Philip Hampton, Independent Non-Executive DirectorView
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Vivienne Cox, Non-Executive Independent DirectorView
Bill Louv, Senior Vice President - Core Business ServicesView
Diana Conrad, Senior Vice President - Human ResourcesView
Roger Connor, President - Global Manufacturing & SupplyView
Abbas Hussain, President Global PharmaceuticalsView
Phil Thomson, Senior Vice President - Global CommunicationsView
Judy Lewent, Non-Executive Independent DirectorView
Hans Wijers, Independent Non-Executive DirectorView
Stephanie Burns, Non-Executive Independent DirectorView
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Urs Rohner, Non-Executive Independent DirectorView
Marvinder Banga, Senior Non-Executive Independent DirectorView
Deryck Maughan, Senior Independent Non-Executive DirectorView
Jesse Goodman, Non-Executive Independent DirectorView
Laurie Glimcher, Non-Executive Independent DirectorView
Nick Hirons, Senior Vice President - Global Ethics and ComplianceView
Sally Jackson, Senior Vice President - Global Communications and CEO OfficeView
James Ford, Senior Vice President General CounselView
Victoria Whyte, Company SecretaryView
Daniel Troy, Sr. VP and General CounselView
Shah Hussain, President - Europe, Japan & EMAPView
Manvinder Banga, Non-Executive DirectorView
David Redfern, Chief Strategy OfficerView
Patrick Vallance, President - Pharmaceuticals R&DView
Stacey Cartwright, Non-Executive Independent DirectorView
Regis Simard, President - Pharmaceutical Supply ChainView
Jonathan Symonds, Independent Non-Executive Chairman of the BoardView
Iain Mackay, Chief Financial Officer, Executive DirectorView
Karenann Terrell, Chief Digital & Technology OfficerView
Deborah Waterhouse, Chief Executive Officer - ViiV HealthcareView
Claire Thomas, Senior Vice President - Human ResourcesView

Stock Performance Indicators

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page